Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
AgomAb Therapeutics N.V. American Depositary Shares (AGMB)
USD12.25
+0.21 (+1.74%)
BE NASDAQ Healthcare Biotechnology
Address
Posthoflei 1/6 2600
Antwerp, BE
Antwerp, BE
CEO
Tim Knotnerus
Website
agomab.com
IPO
2024-05-29
CIK 2104168 ISIN US00860C1027
Description
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD12.25
+0.21 (+1.74%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
124.5K
Beta
1.73
Float Shares
36.13M
Free Float %
73.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.51% | -4.42% | +3.69% | -29.78% | -23.21% | -23.21% | -23.21% | -23.21% | -23.21% | -23.21% | -23.21% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Valuation data will be available after the next weekly refresh.
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
est: 724.6K (-100.0%)
|
683.3K
683.3K – 683.3K
-5.7% YoY
|
819.9K
819.9K – 819.9K
+20.0% YoY
|
901.9K
901.9K – 901.9K
+10.0% YoY
|
1.26M
1.26M – 1.26M
+40.0% YoY
|
1.33M
1.33M – 1.33M
+5.0% YoY
|
| EBITDA |
-62.27M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-62.49M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-60.08M
est: -112.77M (+46.7%)
|
-87.69M
-97.96M – -77.41M
+22.2% YoY
|
-97.35M
-118.41M – -74.01M
-11.0% YoY
|
-112.31M
-134.04M – -90.51M
-15.4% YoY
|
-108.90M
-108.90M – -108.90M
+3.0% YoY
|
-115.59M
-115.59M – -115.59M
-6.1% YoY
|
| SGA |
12.57M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.23
est: -2.31 (+46.8%)
|
-1.75
-2.01 – -1.59
+24.6% YoY
|
-2.08
-2.43 – -1.52
-19.0% YoY
|
-2.20
-2.75 – -1.86
-5.8% YoY
|
-2.23
-2.23 – -2.23
-1.7% YoY
|
-2.37
-2.37 – -2.37
-6.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
32
Total invested
245.30M
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
32
+32 vs prev Q
New positions
32
Closed positions
0
Increased
32
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | EQT FUND MANAGEMENT S.A R.L. | 5.14M +5.1M (+100.0%) | 53.94M +53.9M (+100.0%) | 14.19% +14.190 pp | 5.28% +5.284 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 2 | SANOFI | 2.78M +2.8M (+100.0%) | 29.19M +29.2M (+100.0%) | 7.68% +7.680 pp | 8.69% +8.690 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 3 | CORMORANT ASSET MANAGEMENT, LP | 2.47M +2.5M (+100.0%) | 25.86M +25.9M (+100.0%) | 6.80% +6.803 pp | 1.30% +1.299 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 4 | TCG CROSSOVER MANAGEMENT, LLC | 2.05M +2.1M (+100.0%) | 21.54M +21.5M (+100.0%) | 5.67% +5.666 pp | 0.62% +0.616 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 5 | FEDERATED HERMES, INC. | 1.62M +1.6M (+100.0%) | 16.97M +17.0M (+100.0%) | 4.47% +4.465 pp | 0.03% +0.028 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 6 | CASDIN CAPITAL, LLC | 1.55M +1.6M (+100.0%) | 16.26M +16.3M (+100.0%) | 4.28% +4.277 pp | 1.23% +1.231 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 7 | ANDERA PARTNERS | 1.54M +1.5M (+100.0%) | 16.14M +16.1M (+100.0%) | 4.25% +4.246 pp | 9.12% +9.124 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 8 | FMR LLC | 1.46M +1.5M (+100.0%) | 15.30M +15.3M (+100.0%) | 4.03% +4.025 pp | 0.00% +0.001 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 9 | NANTAHALA CAPITAL MANAGEMENT, LLC | 1.20M +1.2M (+100.0%) | 12.85M +12.9M (+100.0%) | 3.31% +3.312 pp | 0.47% +0.473 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 10 | ABRDN PLC | 707.7K +707.7K (+100.0%) | 7.42M +7.4M (+100.0%) | 1.95% +1.953 pp | 0.01% +0.012 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 11 | PERCEPTIVE ADVISORS LLC | 600.0K +600.0K (+100.0%) | 6.29M +6.3M (+100.0%) | 1.66% +1.656 pp | 0.12% +0.123 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 12 | SAMSARA BIOCAPITAL, LLC | 600.0K +600.0K (+100.0%) | 6.29M +6.3M (+100.0%) | 1.66% +1.656 pp | 0.61% +0.612 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 13 | SIREN, L.L.C. | 411.3K +411.3K (+100.0%) | 4.31M +4.3M (+100.0%) | 1.13% +1.135 pp | 0.12% +0.120 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 14 | LMR PARTNERS LLP | 300.0K +300.0K (+100.0%) | 3.15M +3.1M (+100.0%) | 0.83% +0.828 pp | 0.01% +0.007 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 15 | SEVEN GRAND MANAGERS, LLC | 200.0K +200.0K (+100.0%) | 2.10M +2.1M (+100.0%) | 0.55% +0.552 pp | 0.14% +0.140 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 16 | REDMILE GROUP, LLC | 156.3K +156.3K (+100.0%) | 1.64M +1.6M (+100.0%) | 0.43% +0.431 pp | 0.11% +0.109 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 17 | MILLENNIUM MANAGEMENT LLC | 95.2K +95.2K (+100.0%) | 999.0K +999.0K (+100.0%) | 0.26% +0.263 pp | 0.00% +0.000 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 18 | PFIZER INC | 75.0K +75.0K (+100.0%) | 813.8K +813.8K (+100.0%) | 0.21% +0.207 pp | 0.34% +0.341 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 19 | ALYESKA INVESTMENT GROUP, L.P. | 75.0K +75.0K (+100.0%) | 786.8K +786.8K (+100.0%) | 0.21% +0.207 pp | 0.00% +0.002 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 20 | LAURION CAPITAL MANAGEMENT LP | 50.0K +50.0K (+100.0%) | 524.5K +524.5K (+100.0%) | 0.14% +0.138 pp | 0.02% +0.023 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 21 | BELLEVUE GROUP AG | 50.0K +50.0K (+100.0%) | 524.5K +524.5K (+100.0%) | 0.14% +0.138 pp | 0.01% +0.013 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 22 | SECTORAL ASSET MANAGEMENT INC | 43.5K +43.5K (+100.0%) | 477.3K +477.3K (+100.0%) | 0.12% +0.120 pp | 0.40% +0.395 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 23 | GOLDMAN SACHS GROUP INC | 35.7K +35.7K (+100.0%) | 374.9K +374.9K (+100.0%) | 0.10% +0.099 pp | 0.00% +0.000 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 24 | CITADEL ADVISORS LLC | 35.0K +35.0K (+100.0%) | 367.2K +367.2K (+100.0%) | 0.10% +0.097 pp | 0.00% +0.000 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 25 | BURKEHILL GLOBAL MANAGEMENT, LP | 35.0K +35.0K (+100.0%) | 367.2K +367.2K (+100.0%) | 0.10% +0.097 pp | 0.02% +0.018 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 26 | HRT FINANCIAL LP | 23.7K +23.7K (+100.0%) | 248.0K +248.0K (+100.0%) | 0.07% +0.066 pp | 0.00% +0.001 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 27 | D. E. SHAW & CO., INC. | 15.3K +15.3K (+100.0%) | 160.8K +160.8K (+100.0%) | 0.04% +0.042 pp | 0.00% +0.000 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 28 | TWO SIGMA INVESTMENTS, LP | 14.2K +14.2K (+100.0%) | 149.4K +149.4K (+100.0%) | 0.04% +0.039 pp | 0.00% +0.000 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 29 | JANE STREET GROUP, LLC | 12.8K +12.8K (+100.0%) | 134.2K +134.2K (+100.0%) | 0.04% +0.035 pp | 0.00% +0.000 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 30 | UBS GROUP AG | 6.4K +6.4K (+100.0%) | 67.5K +67.5K (+100.0%) | 0.02% +0.018 pp | 0.00% +0.000 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 31 | MORGAN STANLEY | 3.0K +3.0K (+100.0%) | 31.7K +31.7K (+100.0%) | 0.01% +0.008 pp | 0.00% +0.000 pp | USD10.49 +0.0% | 1 qtrs NEW |
| 32 | SBI SECURITIES CO., LTD. | 2.00 +2.0 (+100.0%) | 21.00 +21.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD10.00 +4.9% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ALPS Medical Breakthroughs ETF SBIO | 0.33% | 703.5K | 0.50% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
Shares Outstanding
49.25M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andrea Sáez Borderías | Chief Development Officer | — | — |
| Ellen Lefever | General Counsel | — | female |
| Paolo Michieli | Founder, Senior Advisor & Member of Scientific Advisory Board | — | male |
| Paul Van Der Horst | Chief Business Officer | — | — |
| Philippe Wiesel | Chief Medical Officer | — | — |
| Pierre Kemula | Chief Financial Officer | — | male |
| Sofie Van Gijsel | Vice President of Investor Relations | — | — |
| Tim Knotnerus | CEO & Executive Director | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AGMB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
